Kardiotoxizität zielgerichteter onkologischer Therapien

Auch bei zielgerichteten molekularen Tumortherapien kann es zum Auftreten von kardiovaskulären Nebenwirkungen kommen. Die kurz- und langfristigen Wirkungen der Behandlungen erfordern Kenntnis der substanzspezifischen Nebenwirkungen und eine sorgfältige Überwachung, Diagnostik und Therapie. Dieser Übersichtsartikel beschäftigt sich mit der Pathophysiologie, der Epidemiologie und dem Management der Kardiotoxizität zielgerichteter molekularer Therapien.

Schlüsselwörter

Kardiotoxizität - Onkologie - Hypertonie - VEGF - BCR/ABL - ALK - Inhibitoren

• Literatur

• 1 Rassaf T, Totzeck M, Backs J. et al. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol 2020; 109: 1197-1222
• 2 Totzeck M, Mincu RI, Rassaf T. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20000 Patients. J Am Heart Assoc 2017; 6: e006278
• 3 Florido R, Smith KL, Cuomo KK. et al. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. J Am Heart Assoc 2017; 6: e006915
• 4 Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008; 14: 14-24
• 5 Hudis CA. Trastuzumab — Mechanism of Action and Use in Clinical Practice. N Engl J Med 2007; 357: 39-51
• 6 de Azambuja E, Procter MJ, van Veldhuisen DJ. et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1–01). J Clin Oncol 2014; 32: 2159-2165
• 7 Cardinale D, Colombo A, Torrisi R. et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910-3916
• 8 Azim H, Azim jr HA, Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev 2009; 35: 633-638
• 9 Lenihan D, Suter T, Brammer M. et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 2012; 23: 791-800
• 10 Perez EA, Koehler M, Byrne J. et al. Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. Mayo Clin Proc 2008; 83: 679-686
• 11 Hall PS, Harshman LC, Srinivas S. et al. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 2013; 1: 72-78
• 12 Alexandre J, Cautela J, Ederhy S. et al. Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc 2020; 9: e018403
• 13 Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies. N Engl J Med 2016; 375: 1457-1467
• 14 Mincu RI, Mahabadi AA, Michel L. et al. Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis. JAMA Netw Open 2019; 2: e198890
• 15 Totzeck M, Schuler M, Stuschke M. et al. Cardio-oncology – strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol Heart Vasc 2019; 280: 163-175
• 16 Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 2015; 7: 122-136
• 17 Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007; 29: 2289-2308
• 18 Cirmi S, El Abd A, Letinier L. et al. Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers (Basel) 2020; 12: 826
• 19 Xiao L, Salem JE, Clauss S. et al. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation 2020; 142: 2443-2455
• 20 Wu P, Oren O, Gertz MA. et al. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management. Curr Oncol Rep 2020; 22: 66
• 21 Grandin EW, Ky B, Cornell RF. et al. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail 2015; 21: 138-144